The FDA approved a supplemental application for Avtozma, Celltrion's tocilizumab biosimilar (tocilizumab-anoh, BLA 761420), dated 2 September 2026. The FDA record available to us names the product, sponsor and application but not the content of the supplement, which may be a labelling, manufacturing or presentation change rather than a new indication.
For prescribers, tocilizumab biosimilars matter because cost is the main barrier to IL-6 blockade in rheumatoid arthritis and giant cell arteritis. The regulatory position in India for this product is not established here; check the CDSCO approval and local availability before assuming it can be substituted.
- Avtozma is a tocilizumab biosimilar from Celltrion
- This FDA action is a supplement to an existing licence; its content is not stated in the record
- Do not assume a new indication or formulation until the updated label is published
- Check CDSCO status and local availability before prescribing in India
Why it matters
Biosimilar tocilizumab is how IL-6 blockade becomes affordable for more patients.
Don't overread it
A licence supplement is not a new indication; the record does not say what changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free